Global Intravenous Solution Market to Reach USD 24,667.69 Million by 2031, Growing at a CAGR of 9.1%
Category : Pharmaceuticals | Published Date : Nov 2024 | Type : Press Release
Intravenous Solution Market Scope & Overview:
In the newly published report, Consegic Business Intelligence states that the Intravenous Solution Market was valued at USD 12,443.55 Million in 2023 and is projected to reach USD 24,667.69 Million by 2031, expanding at a CAGR of 9.1% from 2024 to 2031. Intravenous (IV) solutions are sterile fluids administered through a vein using IV tubing. They are commonly used in healthcare settings for hydration, electrolyte balance, and nutrient delivery, especially in patients who are critically ill, injured, or unable to take oral medications.
The report comprises the Intravenous Solution Market Share, Size & Industry Analysis, By Type (Crystalloid, Colloids), By End-User (Hospitals, Clinics, Homecare, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and Forecast, 2024–2031.
The report contains detailed information on Intravenous Solution Market Trends, Opportunities, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profile, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraints or Challenges, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.
Increasing prevalence of chronic diseases and growing demand for hydration and nutrient delivery therapies are driving the growth of the intravenous solution market. However, the availability of non-invasive treatment alternatives may pose challenges to market expansion.
Segmental Analysis :
By Type, the market is segmented into Crystalloid and Colloids.
- Crystalloid solutions dominated the market in 2023, due to their widespread use in hydration, resuscitation, and electrolyte balance maintenance. Crystalloid IV solutions are favored for their lower cost and ease of availability.
- Colloids are projected to witness the fastest CAGR, driven by their superior fluid retention properties and increasing usage in critical care for plasma volume expansion.
By End-User, the market segments are Hospitals, Clinics, Homecare, and Others.
- Hospitals accounted for the largest market share of 53.28% in 2023, attributed to the extensive use of IV solutions for patient hydration, medication delivery, and critical care.
- Clinics are expected to grow at the fastest rate, supported by the increasing adoption of IV therapy services for nutrient delivery and rapid rehydration.
Based on regions, the global market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
- North America held the largest market share in 2023, valued at USD 4,629.00 Million, driven by the high prevalence of chronic diseases and advanced healthcare infrastructure.
- Asia-Pacific is expected to register the fastest CAGR of 9.8% during the forecast period, fueled by increasing investments in healthcare infrastructure and rising demand for IV therapies.
| Report Attributes | Report Details |
| Study Timeline | 2018-2031 |
| Market Size in 2031 | USD 24,667.69 Million |
| CAGR (2024-2031) | 9.1% |
| By Type | Crystalloid, Colloids |
| By End-User | Hospitals, Clinics, Homecare, Others |
| By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
Top Key Players & Competitive Landscape :
The intravenous solution market is characterized by strong competition among key industry players who focus on innovation, product development, and strategic collaborations. The analysis highlights leading companies, assessing their product offerings, financial performance, and recent developments.
List of prominent players in the Intravenous Solution Industry:
- Baxter
- AdvaCare Pharma®
- Puerto Life Sciences Pvt. Ltd.
- Fresenius Kabi AG
- ICU Medical, Inc.
- B. Braun Medical Inc.
- JW Holdings
- Pfizer Inc.
- Otsuka Pharmaceutical Factory, Inc.
Recent Industry Developments :
- 2024: Baxter increased U.S. allocation levels of its high-demand IV solutions, from 40% to 60% for direct customers, aiming to meet rising hospital demand.
- October 2024: B. Braun Medical Inc. announced a 20% increase in production of IV fluids at its facilities in California and Florida, in collaboration with the Administration for Strategic Preparedness and Response (ASPR).
- September 2023: Eisai Co., Ltd. and Biogen Inc. received approval for LEQEMBI® Intravenous Infusion in Japan, enhancing treatment options for Alzheimer's disease.
- 2022: Fresenius Kabi acquired Ivenix Inc., integrating advanced infusion therapy solutions with its portfolio, enhancing the company's product offerings.
